NASDAQ:RKDA - Arcadia Biosciences Stock Price, Price Target & More

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

Arcadia Biosciences Inc (NASDAQ:RKDA) released its quarterly earnings data on Wednesday, May, 9th. The basic materials company reported ($4.86) earnings per share for the quarter. The basic materials company earned $0.21 million during the quarter. Arcadia Biosciences had a negative net margin of 686.10% and a negative return on equity of 259.46%. View Arcadia Biosciences' Earnings History.

Arcadia Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Arcadia Biosciences.

2 Wall Street analysts have issued twelve-month price targets for Arcadia Biosciences' shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Arcadia Biosciences' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 169.9% from the stock's current price. View Analyst Ratings for Arcadia Biosciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Arcadia Biosciences include China Green Agriculture (CGA), SenesTech (SNES), Kiwa Bio-Tech Products Group (KWBT), Eden Research (EDEN), Bion Environmental Technologies (BNET), Cavitation Technologies (CVAT) and Syngenta (SYT).

(RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

Media stories about RKDA stock have been trending somewhat positive on Sunday, Accern reports. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arcadia Biosciences earned a daily sentiment score of 0.05 on Accern's scale. They also assigned headlines about the basic materials company an impact score of 43.00 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of RKDA stock can currently be purchased for approximately $7.41.

Arcadia Biosciences has a market capitalization of $18.38 million and generates $4.03 million in revenue each year. The basic materials company earns $-15,700,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Arcadia Biosciences employs 42 workers across the globe.

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]